Zacks Investment Research
27 Jan 2026, 15:56 UTC · 34w ago
Verdict
Headline leans bullish. We score CRVS +0.80 across three claims.
Score confirms the headline.
Leans bullish
From its wording — no explicit rating
+0.80strongly bullish
What the story claims
3 claims · scored −1 bearish … +1 bullish
Analysts have collectively revised earnings estimates for Corvus Pharmaceuticals (CRVS) upward.
More positive than 77% of claims this week
The mean analyst price target for Corvus Pharmaceuticals is $28.83, representing a 25.3% potential upside from its last close of $23.01.
Continue reading
5 related stories
More positive than 86% of ticker scores this week
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More positive than 51% of claims this week
Corvus Pharmaceuticals shares experienced a 208.9% price increase over the preceding four weeks.
More positive than 42% of claims this week
Which stocks this story touches
More positive than 86% of ticker scores this week
The stock has gained over 200% recently, with a mean price target indicating further upside and positive earnings estimate revisions.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Seeking Alpha
4h ago
−45.5%
Price is moving against the score
$12.54 vs $23.01 close before publication (Jan 26) · not market-adjusted
CRVS chart →
